1-3 of 3
Karolyn K. Morris
Close
Sort by
Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Ryan C. Lynch, MD, Ryan D. Cassaday, MD, Stephen D. Smith, MD, Jonathan R. Fromm, MD PhD, Andrew J. Cowan, MD, Edus H. Warren, MD PhD, Mazyar Shadman, MDMPH, Andrei R Shustov, MD, Brian G. Till, MD, Chaitra S. Ujjani, MD, Edward Libby, MD, Mary Philip, MDPhD, Hilary Coye, PA-C, Christen N. Martino, NP, Sandra Kanan, MSN, ARNP, Karolyn K. Morris, BA, Heather A. Rasmussen, BS, Sanaz Behnia, MD, Margaret E. Nartea, BS, Jenna M. Voutsinas, MPH, Ajay K. Gopal, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–18.
https://doi.org/10.1182/blood-2020-133763
Published: 2020
Journal Articles

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, BA, Sanaz Behnia, MD, Qian Vicky Wu, PhD, Jenna M. Voutsinas, MPH, Ryan C. Lynch, MD, Elizabeth Krakow, MD, Heather A. Rasmussen, BS, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1596.
https://doi.org/10.1182/blood-2019-126086
Published: 2019
Journal Articles

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, Heather A. Rasmussen, BS, Pamela S. Becker, MD, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2954.
https://doi.org/10.1182/blood-2018-99-115476
Published: 2018